WebJenny Thirlway; Jenny Thirlway. Senior Director at Iksuda Therapeutics. Join to edit. About. Jen leads Iksuda’s ADC programmes including the pre-clinical demonstration of Iksuda’s proprietary PermaLink conjugation chemistry, exemplification of novel toxin platforms and the evaluation of partnered antibodies/alternative scaffolds focussed on ...
Overcoming Challenges in the Development of Anticancer ADCs
WebBibTeX @MISC{Thirlway04n-and, author = {Jenny Thirlway and Ian J. Turner and Christopher T. Gibson and Laurence Gardiner and Kevin Brady and Stephanie Allen and Clive J. Roberts and Panos Soultanas}, title = {N- and C-domains of DnaB and}, year = {2004}} WebDr. Jenny Thirlway School of Chemistry & Manchester Interdisciplinary Biocentre, The University of Manchester, 131 Princess Street, Manchester M1 7DN (UK) These authors contributed equally to this work. Search for more papers by this author Dr. Richard Lewis, Dr. Richard Lewis FHMS, University of Surrey, Guildford, Surrey, GU27XH (UK) dr houck cardiology naples fl
CiteSeerX — N- and C-domains of DnaB and - Pennsylvania State …
WebDec 20, 2024 · At Iksuda, Jenny Thirlway has 3 colleagues including David Simpson (CEO), Ian Evetts (Business)… Industry Colleagues. In the Biotechnology industry, Jenny Thirlway … WebJenny Thirlway. Senior Director, Development Program Team Leader. Michael Owen. Non-Executive Director. Alan Lamb. Non-Executive Director. Source: iksuda.com. Report incorrect company information. Key Executive Tracking. Receive notifications of key executive changes. Get started. Executives of similar companies. WebDec 14, 2024 · Jenny Thirlway from Glythera presented on linker technology developed by her company. The technology, called PermaLink¬Æ, has improved stability, efficacy and tolerability as compared to maleimide linker technology in vitro and in vivo. In addition, Jenny presented data on novel payloads targeting CDK11 and inducing apoptosis in … dr houdek rapid city sd